PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — UBS Global Consumer Conference March 2013
26 slides from PT Kalbe Farma Tbk's conference presentation, March 2013
Slide 1: UBS Global Consumer Conference
UBS Global Consumer Conference Boston, March 2013 Excellence in Execution
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2012 indicative unaudited results of the Company. The info
Slide 3: Table of Contents
Table of Contents BUSINESS OVERVIEW 2012 4 OUR STRATEGIES IN 2013 22 Excellence in Execution 3
Slide 4: Business Overview 2012
BUSINESS OVERVIEW 2012 4 Excellence in Execution
Slide 5: Corporate Overview
Corporate Overview Largest Publicly-Listed Pharmaceuticals Company in Southeast Asia • Established in 1966 and headquartered in Jakarta • A public company since 1991 and listed in the Indonesia Stock Exchange • The largest publicly-listed pharmaceuticals company in Southeast Asia • Sales breakdown b
Slide 6: Indonesia's Health Spending Trends
Indonesia’s Health Spending Trends • Total expenditure on health averaged 2.1% of Healthcare Expenditure/GDP 2010 GDP over the 11 year period 1999-2009. 5.00% 4.8% 1 • In Q4 2009, the new Healthcare Law has been 4.50% 4.1% 3.8% 1 4.00% 3.5% approved and provides guideline for Government 3.50% 3.3% 0
Slide 7: Indonesian Pharmaceuticals Market
Indonesian Pharmaceuticals Market Highly Fragmented Industry with more than 200 Pharmaceutical Players Total Market (ITMA) Pharmacy (IPA) Hospital (IHPA) YTD 12 2011 YTD 12 2011 YTD 12 2011 b c b b c a c d a d a 5% 5% d e KALBE 6% KALBE 7% 5% e 7% 5% 4% e 7% 4% KALBE 5% 5% 4% GROUP GROUP 4% f f 4% f
Slide 8: Prescription Pharmaceuticals Division
Prescription Pharmaceuticals Division Comprehensive Product Range Targeted to All Income Groups Sales Contribution By Number of Product Categories Products Therapeutic Class YTD 09 2012 • General Anti-Infectives • Hospital Solutions Licensed • Oncology Licensed 89 • Blood and Blood Forming Organs Pr
Slide 9: Prescription Pharmaceuticals Division
Prescription Pharmaceuticals Division New Production Facilities • Completed new production facility for generic drugs in Cikarang • Construction of oncology plant in Pulogadung Excellence in Execution 9
Slide 10: Consumer Health Division
Consumer Health Division Strong Brand Equity with Leading Market Position Market share of Kalbe’s brands YTD December 2011 Therapeutic Class Kalbe’s Products Market Share by Volume Antacid Promag, Waisan 77.4%* Anti Diarrhea Neo Entrostop 44.8%** Cough Remedies Komix, Woods, Mextril, Mixadin 39.1% C
Slide 11: Nutritionals Division
Nutritionals Division Complete Range of Nutritional Products • Catered to expecting & lactating mothers, babies, toddlers, children, tweens and adults. Expecting Lactating Baby Toddler Kid Tween Teen 25+ 35+ Clinical Excellence in Execution 11
Slide 12: Nutritionals Division
Nutritionals Division Relatively Low Milk per Capita Consumption Milk per Capita Consumption (kg) 40 -2.3% 35 30 25 20 1.6% 15 0.5% 10 2.7% 1.1% 1.6% 5 0 Indonesia Thailand Philippines Malaysia Vietnam South Korea 2006 2.29 13.55 1.48 7.49 2.71 35.7 2007 2.39 12.28 1.51 8.15 2.39 34.92 2008 2.5 12.9
Slide 13: Business Overview 2012
Business Overview 2012 • Launched new innovative products • Acquisition of PT Hale International • Established a joint venture company PT Kalbe Milko Indonesia Excellence in Execution 13
Slide 14: Nutritionals Division
Nutritionals Division Multi Channel Customer Touch Points Kalbe e-store - the 1st Online Nutrition Store in Indonesia Nutritionals Division launched new channel of consumer order through hotline service Kalbe Home Delivery 500-880 and online shopping through www.kalbestore.com . Kalbe Family Reward
Slide 15: Distribution & Logistics Division
Distribution & Logistics Division The Most Extensive Distribution Network RDC Branches Cities 2 65 47 Excellence in Execution 15
Slide 16: Distribution & Logistics Division
Distribution & Logistics Division Major Third Party Principals by Category • Expansion of distribution and logistics facilities Banjarmasin Jember Surakarta Banda Aceh Denpasar • Multi-channel customer touch points : Kalbe e-store, Kalbe Family Rewards Card, Kalbe Home Delivery, Kalbe Customer Care
Slide 17: Distribution & Logistics Division
Distribution & Logistics Division Major Third Party Principals by Category Prescription Medical Instrument Fine Chemical Pharmaceuticals Consumer & Diagnostic Raw Materials Excellence in Execution 17
Slide 18: International Overview 2012
International Overview 2012 • Continued regional expansion Diabetasol and Extra Joss Events in the Philippines Long-lasting kick Excellence in Execution 18
Slide 19: Indicative Results 2012
Indicative Results 2012 Strong Top Line Growth in All Segments Net Sales (in Rp Bn) 24.9% 31 Dec 2011 (Audited) 31 Dec 2012 (Unaudited) 13,630 10,912 33.7% 18.4% 24.5% 16.8% 5,179 3,873 3,288 3,012 2,778 2,420 1,842 2,151 Prescription PharmaceuticalsConsumer Health Nutritionals Distribution & Logist
Slide 20: Indicative Results 2012
Indicative Results 2012 Improved operating expenses efficiency Gross Profit Margin Operating Expenses to Net Sales Ratios 32.8% 31.6% -1.2% - 3.0% 0.8% 0.7% 5.4% 4.9% 50.9% 47.8% Selling & Marketing General & 26.6% 26.0% Administrative Research & Development 31 Dec 2011 31 Dec 2012 31 Dec 2011 31 De
Slide 21: Indicative Results 2012
Indicative Results 2012 Strong Earnings Growth Income Before Tax Net Income (in Rp bn) (in Rp bn) +15.1% +16.8% 2,288 1,732 1,987 1,482 31 Dec 2011 (Audited) 31 Dec 2012 (Unaudited) 31 Dec 2011 (Audited) 31 Dec 2012 (Unaudited) • Income before tax margin declined from • Net income margin declined fr
Slide 22: Our Strategies in 2013
OUR STRATEGIES IN 2013 22 Excellence in Execution
Slide 23: Strategies for 2013
Strategies for 2013 1. Improve marketing and sales effectiveness CORPORATE BRANDING 2. Strengthen business portfolio through innovation and M&A Excellence in Execution 23
Slide 24: Strategies for 2013
Strategies for 2013 3. Go global – deeper ASEAN penetration 4. Expand distribution coverage with more product offering New RDC New branches and existing branch capacity expansion Additional trucks & motorcycles 5. Enhance human capital development Excellence in Execution 24
Slide 25: Outlook 2013
Outlook 2013 Earnings Guidance 2013 1. Year-on-year Sales Growth 15% - 18% 2. Operating Profit Margin 16.0% -17.0% 3. Earnings per Share growth of 15% - 18% 4. Dividend payout ratio minimum 50% • Capex Rp 1 – 1.5 Tn for production capacity and distribution network expansion • Cancellation of Treasur
Slide 26: Thank You
THANK YOU For further information: PT Kalbe Farma Tbk. Jalan Let.Jend. Suprapto Kav. 4 Jakarta 10510, Indonesia Tel. : 62-21-42873888 Fax. : 62-21-42873678 Email : vidjongtius@kalbe.co.id jhandajani@kalbe.co.id investor.relations@kalbe.co.id Website : www.kalbe.co.id Excellence in Execution 26
PT Kalbe Farma — UBS Global Consumer Conference March 2013 on 6ix